Evidence map›Paper›PMID 41091182›Full record

ArticleAnnals of hematology2025

Total thrombus formation analysis in patients with myeloid neoplasia and thrombocytopenia.

Katharina Freitag, Georg-Nikolaus Franke, Maria Weise, Carmen Herling, Tristan Klöter, Marco Herling, Annelie Siegemund, Madlen Jentzsch, Sirak Petros, Reinhard Henschler and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Katharina FreitagDivision of Hemostaseology, Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University of Leipzig Medical Center, Leipzig, Germany.
Georg-Nikolaus FrankeDivision of Hematology and Cellular Therapy, Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University of Leipzig Medical Center, Leipzig, Germany.
Maria WeiseDivision of Hemostaseology, Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University of Leipzig Medical Center, Leipzig, Germany.
Carmen HerlingDivision of Hematology and Cellular Therapy, Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University of Leipzig Medical Center, Leipzig, Germany.
Tristan KlöterDivision of Hemostaseology, Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University of Leipzig Medical Center, Leipzig, Germany.
Marco HerlingDivision of Hemostaseology, Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University of Leipzig Medical Center, Leipzig, Germany.
Annelie SiegemundDivision of Hemostaseology, Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University of Leipzig Medical Center, Leipzig, Germany.
Madlen JentzschDivision of Hematology and Cellular Therapy, Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University of Leipzig Medical Center, Leipzig, Germany.
Sirak PetrosDivision of Hemostaseology, Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University of Leipzig Medical Center, Leipzig, Germany.
Reinhard HenschlerInstitute of Transfusion Medicine, University of Leipzig Medical Center, Leipzig, Germany.
Klaus H MetzelerDivision of Hematology and Cellular Therapy, Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University of Leipzig Medical Center, Leipzig, Germany.
Christian PfrepperDivision of Hemostaseology, Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University of Leipzig Medical Center, Leipzig, Germany. Christian.pfrepper@medizin.uni-leipzig.de.ORCID http://orcid.org/0000-0002-0485-7402

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with hematologic malignancies often require platelet transfusions, but platelet count alone does not sufficiently predict bleeding risk. T-TAS HD-Chip is designed to evaluate the hemostatic function in whole blood samples from thrombocytopenic patients. This study aimed to investigate T-TAS HD-chip in thrombocytopenic patients with myeloid neoplasia. Samples from thrombocytopenic patients with myeloid neoplasia were prospectively collected. The area under the curve (AUC), occlusion start time and occlusion time of T-TAS, platelet count, von Willebrand factor and thrombin generation were measured, and the association of these markers with platelet transfusion, parenteral nutrition and bleeding events was evaluated. A total of 67 samples were collected from 28 patients. No occlusion in T-TAS was detected in samples with platelet counts ≤20 × 10

Indexed as

Hematologic NeoplasmsThrombocytopeniaThrombosisAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPlatelet CountPlatelet TransfusionProspective StudiesLeukemiaMyeloid neoplasiaPlatelet functionThrombocytopeniaT-TAS

Identifiers

PMID41091182
PMCPMC12619771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.